In a recent study from the University of Colorado, researchers found that a single dose of AZD7442 is effective in preventing COVID-19.
In the study, the team conducted a phase 3 clinical trial. The participants had an increased risk for an inadequate response to vaccination against COVID-19, an increased risk for exposure to COVID-19, or both.
The researchers tested a total of 5,197 participants.
These people were assigned to receive a single dose of AZD7442 (two consecutive intramuscular injections of tixagevimab and cilgavimab) or saline placebo.
The participants were followed for up to 183 days.
The researchers found that 35.3 and 34.2 percent of participants in the AZD7442 and placebo groups, respectively, had at least one adverse event, which was mostly mild or moderate in severity.
Symptomatic COVID-19 occurred in 0.2 and 1.0 percent of participants in the AZD7442 and placebo groups, respectively.
The team found the COVID-19 risk reduction was 82.8 percent at extended follow-up at six months.
There were five cases of severe or critical COVID-19 and two COVID-19-associated deaths, all in the placebo group.
These findings support the use of a single dose of AZD7442 (two consecutive intramuscular injections) for the prevention of symptomatic and severe COVID-19.
If you care about COVID, please read studies about new oral drug that may prevent Covid-19 death, and these drugs work well against BA.2 Omicron variant.
For more information about COVID, please see recent studies about durable immunity against COVID-19 variants, and results showing a universal antibody therapy for all COVID-19 variants.
The research is published in the New England Journal of Medicine and was conducted by Myron J. Levin et al. AstraZeneca manufactures AZD7442 and funded the study.
Copyright © 2022 Knowridge Science Report. All rights reserved.